EUROPEAN NEUROLOGICAL REVIEW – VOLUME 14 ISSUE 1 – SUMMER 2019

Welcome to the summer edition of European Neurological Review. Neurology and neuroscience are diverse fields that touch on almost every other discipline, and the articles in this issue reflect the scope of the field, as well as highlight key challenges and innovations. We begin with two expert interviews. Raquel Gil-Gouvia discusses cognitive dysfunction during migraine attacks, […]

Raquel Gil-Gouveia MD, PhD is the Director of Neurology and of the Headache Centre in Hospital da Luz, Lisboa. She has been a researcher in headache since 1998, having worked in the clinical and pathophysiological aspects of cluster headache, headache associated with endovascular procedures and migraine. In migraine, she focused on the impact and disability […]

Ambra Stefani was born in Italy, where she performed her medical training at the University of Verona. After that she moved to Innsbruck, Austria, where she is currently working as resident and PhD student in the Department of Neurology, Medical University of Innsbruck, Austria. Ambra Stefani has been a member of the sleep research group, […]

Brain metastases (BM) are the most frequent among intracranial brain tumours and their incidence is rising as therapeutic advances are improving the survival of patients with advanced cancer. The incidence of BM has been calculated as 9–17% based on various studies, although the true incidence is thought to be higher.1 Patients with BM have a […]

In 2018, two randomised controlled trials, DAWN (the Clinical Mismatch in the Triage of Wake up and Late Presenting Strokes Undergoing Neurointervention with Trevo Thrombectomy Procedure) and DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischaemic Stroke 3), implemented computed tomography (CT) and magnetic resonance imaging (MRI) in patients with stroke.1,2 These studies showed the […]

The burdens of Parkinson’s disease (PD) are undeniably serious and increasing while various unmet needs remain, especially the absence of disease-modifying therapies and the difficulty of finding new treatments that are effective in patients.1–7 Although this seems a discouraging situation, considerable advances in understanding the pathophysiology of PD and the identification of new targets for […]

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disorder of the central nervous system that is characterised by episodes of neurological dysfunction and eventually, neurodegeneration and the progressive accumulation of disability.1,2 Approximately 85% of patients with MS initially present with relapsing-remitting MS (RRMS), which is characterised by periodic acute exacerbations of disease activity (relapses) followed by […]

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a peripheral neuropathy that can affect motor and/or sensory nerves, and lead to both loss of strength and altered sensation.1 Common first-line treatments for CIDP are immunoglobulins (Igs), corticosteroids and plasma exchange.2 Intravenous immunoglobulins (IVIgs) have been shown to be efficacious in maintaining or improving strength and disability in […]